Despite improvements in diagnostics and therapy over the past few decades, diagnosis of systemic lupus erythematosus is still associated with significant mortality and severe burden. Belimumab is the only new drug licensed during the past 50 years for systemic lupus erythematosus; therefore, any success of a drug in the pipeline raises new hope for patients and the scientific community.

中文翻译：

---

Baricitinib治疗系统性红斑狼疮

尽管在过去的几十年中在诊断和治疗方面有了改进，但系统性红斑狼疮的诊断仍与显着的死亡率和严重的负担有关。Belimumab是过去50年来唯一被许可用于系统性红斑狼疮的新药。因此，任何一种成功的药物都会为患者和科学界带来新的希望。